Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Healthcare worker measuring tension on a patient © Credit Rama George Alleyne, World Bank

Similar stories

Immediate policy changes urgently needed as drug-resistant malaria spreads in East Africa

The efficacy of artemisinin derivatives, the cornerstone of current treatments for malaria, is being compromised in Africa where over 1,000 children are estimated to die each day from the disease. The spread of artemisinin-resistant malaria parasites across East Africa and beyond could result in millions more deaths without immediate health policy changes, warn experts in a paper published in Science.